子宫内膜癌及癌前病变的生育力保护和保存OA
Fertility preservation and protection in endometrial cancer and precancerous lesions
近年来,子宫内膜癌及癌前病变的发病呈现年轻化趋势,越来越多有生育需求的女性面临着在肿瘤治疗与保留生育功能(简称"保育")的艰难抉择.保育治疗虽为这部分患者提供了妊娠可能,但疾病本身和治疗对子宫内膜和卵巢功能的潜在损害不容忽视.子宫方面,长期保育治疗可导致子宫内膜萎缩、纤维化甚至宫腔粘连,严重影响胚胎着床;而卵巢则因原发性功能障碍或机体代谢异常(如代谢综合征和肥胖等)及治疗药物影响,面临卵巢储备功能下降与排卵障碍的问题.这些都会导致患者生育力受损.因此,生育力保护应贯穿于保育治疗全过程:一方面需优化治疗方案,缩短疗程、减少子宫内膜损伤,并在完全缓解后恰当采用干细胞、富血小板血浆、低强度聚焦超声等新兴技术修复子宫内膜微环境;另一方面应重视卵巢功能评估与干预,对高危患者及时提供胚胎、卵子或卵巢组织冻存等生育力保存手段,并结合生活方式调整与代谢管理改善整体生殖预后.值得关注的是,基于分子分型的精准诊疗和免疫治疗的探索,正为扩大保育治疗适应证、提升疗效与安全性开辟新路径.未来,唯有整合妇科肿瘤、生殖医学、内分泌及遗传等多学科力量,实施个体化、全周期的综合管理,方能在保障患者生命安全的前提下,真正实现其生育愿望.
In recent years,the incidence of endometrial cancer and its precancerous lesions has shown a trend of younger onset,placing more women with childbearing desires in a difficult dilemma between cancer treatment and fertility preservation.Although fertility-sparing treatments provide these patients with the possibility of pregnancy,the potential damage to endometrial and ovarian function caused by the disease itself and its treatment cannot be overlooked.Regarding the uterus,prolonged fertility-sparing therapy may lead to endometrial atrophy,fibrosis,and even intrauterine adhesions,significantly impairing embryo implantation.For the ovaries,primary dysfunction,metabolic abnormalities(such as metabolic syndrome and obesity),and the impact of therapeutic drugs may result in reduced ovarian reserve and ovulation disorders,ultimately compromising fertility.Therefore,fertility protection should be performed throughout the entire fertility-sparing treatment process:on one hand,treatment regimens should be optimized to shorten duration and minimize endometrial damage,and emerging technologies such as stem cell,platelet-rich plasma(PRP),and low-intensity focused ultrasound(LIFU)should be appropriately employed to repair the endometrial microenvironment after complete remission;on the other hand,pay attention to ovarian function assessment and intervention,offer fertility preservation options in a timely manner to the high-risk patients,including embryo,oocyte,or ovarian tissue cryopreservation,and improve overall reproductive outcomes through lifestyle modifications and metabolic management.Notably,the exploration of precision diagnosis and treatment based on molecular subtyping and immunotherapy is paving new pathways to expanding the indications for fertility-sparing therapy and enhancing efficacy and safety.Looking ahead,only through an integrated,multidisciplinary approach involving gynecologic oncology,reproductive medicine,endocrinology and genetics and by implementing individualized,life-course comprehensive management can we truly fulfill patients' fertility aspirations while ensuring their life safety.
陈晓军
同济大学附属第十人民医院,上海 200072
医药卫生
子宫内膜癌子宫内膜不典型增生生育力保护生育力保存保留生育功能治疗
endometrial canceratypical endometrial hyperplasiafertility protectionfertility preservationfertility-sparing treatment
《中国实用妇科与产科杂志》 2026 (5)
505-510,6
国家重点研发计划(2025ZD0545900,2025ZD0545902) National Key Research and Development Program of China(2025ZD0545900,2025ZD0545902)
评论